PharmacovigilanceOfficial

Commission grants marketing authorisation for Revolution Medicines' daraxonrasib product Rasonque

🇪🇺 European Commission (Union Register) · Mon 16 Nov 2026

The European Commission has authorised Rasonque (daraxonrasib) for Revolution Medicines Netherlands B.V., though the Union Register entry does not state the indication or any conditions.

The European Commission has granted a new marketing authorisation for Rasonque, whose active substance is daraxonrasib, to Revolution Medicines Netherlands B.V. The authorisation was issued through Commission Decision (2026) 8340 of 16 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Official source: European Commission (Union Register) ↗

Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.